CRP and adiponectin and its oligomers in the metabolic syndrome: Evaluation of new laboratory-based biomarkers

Sridevi Devaraj, Michael M. Swarbrick, Uma Singh, Beverley Adams-Huet, Peter J. Havel, Ishwarla Jialal

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

The metabolic syndrome (MetS) confers an increased risk for diabetes and cardiovascular disease. Although high-sensitive C-reactive protein (hsCRP) concentrations are higher and adiponectin concentrations lower in MetS, there is no reliable biochemical measure that can capture its various features. We evaluated whether hsCRP, adiponectin, or the ratio of adiponectin or its oligomers, especially the high-molecular-weight (HMW) oligomer, to hsCRP predict MetS in 123 subjects with MetS compared with that in 91 healthy control subjects. MetS subjects had significantly higher hsCRP levels and lower total adiponectin and oligomer levels relative to control subjects (P < .0001). The HMW/total adiponectin and adiponectin/CRP ratios were significantly lower in MetS subjects than control subjects (P < .005). The odds ratio (OR) of MetS using the 75th percentile cutoff for CRP was 3.8 (95% confidence interval [CI], 2.1-6.8) and equivalent to low total adiponectin (OR, 2.5; 95% CI, 1.3-4.5), its oligomers, or the adiponectin/ hsCRP ratio (OR, 2.6; 95% CI, 1.5, 4.8). Thus, measurements of CRP, adiponectin, or its oligomers provide robust biomarkers for predicting MetS.

Original languageEnglish (US)
Pages (from-to)815-822
Number of pages8
JournalAmerican Journal of Clinical Pathology
Volume129
Issue number5
DOIs
StatePublished - May 2008

Fingerprint

Adiponectin
Biomarkers
C-Reactive Protein
Odds Ratio
Confidence Intervals
Molecular Weight
Healthy Volunteers
Cardiovascular Diseases

Keywords

  • Adiponectin
  • Biomarker
  • C-reactive protein
  • Metabolic syndrome

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

CRP and adiponectin and its oligomers in the metabolic syndrome : Evaluation of new laboratory-based biomarkers. / Devaraj, Sridevi; Swarbrick, Michael M.; Singh, Uma; Adams-Huet, Beverley; Havel, Peter J.; Jialal, Ishwarla.

In: American Journal of Clinical Pathology, Vol. 129, No. 5, 05.2008, p. 815-822.

Research output: Contribution to journalArticle

Devaraj, Sridevi ; Swarbrick, Michael M. ; Singh, Uma ; Adams-Huet, Beverley ; Havel, Peter J. ; Jialal, Ishwarla. / CRP and adiponectin and its oligomers in the metabolic syndrome : Evaluation of new laboratory-based biomarkers. In: American Journal of Clinical Pathology. 2008 ; Vol. 129, No. 5. pp. 815-822.
@article{f65ac5719db142209057edeca874f4ec,
title = "CRP and adiponectin and its oligomers in the metabolic syndrome: Evaluation of new laboratory-based biomarkers",
abstract = "The metabolic syndrome (MetS) confers an increased risk for diabetes and cardiovascular disease. Although high-sensitive C-reactive protein (hsCRP) concentrations are higher and adiponectin concentrations lower in MetS, there is no reliable biochemical measure that can capture its various features. We evaluated whether hsCRP, adiponectin, or the ratio of adiponectin or its oligomers, especially the high-molecular-weight (HMW) oligomer, to hsCRP predict MetS in 123 subjects with MetS compared with that in 91 healthy control subjects. MetS subjects had significantly higher hsCRP levels and lower total adiponectin and oligomer levels relative to control subjects (P < .0001). The HMW/total adiponectin and adiponectin/CRP ratios were significantly lower in MetS subjects than control subjects (P < .005). The odds ratio (OR) of MetS using the 75th percentile cutoff for CRP was 3.8 (95{\%} confidence interval [CI], 2.1-6.8) and equivalent to low total adiponectin (OR, 2.5; 95{\%} CI, 1.3-4.5), its oligomers, or the adiponectin/ hsCRP ratio (OR, 2.6; 95{\%} CI, 1.5, 4.8). Thus, measurements of CRP, adiponectin, or its oligomers provide robust biomarkers for predicting MetS.",
keywords = "Adiponectin, Biomarker, C-reactive protein, Metabolic syndrome",
author = "Sridevi Devaraj and Swarbrick, {Michael M.} and Uma Singh and Beverley Adams-Huet and Havel, {Peter J.} and Ishwarla Jialal",
year = "2008",
month = "5",
doi = "10.1309/RN84K51B2JJY1Y0B",
language = "English (US)",
volume = "129",
pages = "815--822",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "5",

}

TY - JOUR

T1 - CRP and adiponectin and its oligomers in the metabolic syndrome

T2 - Evaluation of new laboratory-based biomarkers

AU - Devaraj, Sridevi

AU - Swarbrick, Michael M.

AU - Singh, Uma

AU - Adams-Huet, Beverley

AU - Havel, Peter J.

AU - Jialal, Ishwarla

PY - 2008/5

Y1 - 2008/5

N2 - The metabolic syndrome (MetS) confers an increased risk for diabetes and cardiovascular disease. Although high-sensitive C-reactive protein (hsCRP) concentrations are higher and adiponectin concentrations lower in MetS, there is no reliable biochemical measure that can capture its various features. We evaluated whether hsCRP, adiponectin, or the ratio of adiponectin or its oligomers, especially the high-molecular-weight (HMW) oligomer, to hsCRP predict MetS in 123 subjects with MetS compared with that in 91 healthy control subjects. MetS subjects had significantly higher hsCRP levels and lower total adiponectin and oligomer levels relative to control subjects (P < .0001). The HMW/total adiponectin and adiponectin/CRP ratios were significantly lower in MetS subjects than control subjects (P < .005). The odds ratio (OR) of MetS using the 75th percentile cutoff for CRP was 3.8 (95% confidence interval [CI], 2.1-6.8) and equivalent to low total adiponectin (OR, 2.5; 95% CI, 1.3-4.5), its oligomers, or the adiponectin/ hsCRP ratio (OR, 2.6; 95% CI, 1.5, 4.8). Thus, measurements of CRP, adiponectin, or its oligomers provide robust biomarkers for predicting MetS.

AB - The metabolic syndrome (MetS) confers an increased risk for diabetes and cardiovascular disease. Although high-sensitive C-reactive protein (hsCRP) concentrations are higher and adiponectin concentrations lower in MetS, there is no reliable biochemical measure that can capture its various features. We evaluated whether hsCRP, adiponectin, or the ratio of adiponectin or its oligomers, especially the high-molecular-weight (HMW) oligomer, to hsCRP predict MetS in 123 subjects with MetS compared with that in 91 healthy control subjects. MetS subjects had significantly higher hsCRP levels and lower total adiponectin and oligomer levels relative to control subjects (P < .0001). The HMW/total adiponectin and adiponectin/CRP ratios were significantly lower in MetS subjects than control subjects (P < .005). The odds ratio (OR) of MetS using the 75th percentile cutoff for CRP was 3.8 (95% confidence interval [CI], 2.1-6.8) and equivalent to low total adiponectin (OR, 2.5; 95% CI, 1.3-4.5), its oligomers, or the adiponectin/ hsCRP ratio (OR, 2.6; 95% CI, 1.5, 4.8). Thus, measurements of CRP, adiponectin, or its oligomers provide robust biomarkers for predicting MetS.

KW - Adiponectin

KW - Biomarker

KW - C-reactive protein

KW - Metabolic syndrome

UR - http://www.scopus.com/inward/record.url?scp=44849110323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44849110323&partnerID=8YFLogxK

U2 - 10.1309/RN84K51B2JJY1Y0B

DO - 10.1309/RN84K51B2JJY1Y0B

M3 - Article

C2 - 18426744

AN - SCOPUS:44849110323

VL - 129

SP - 815

EP - 822

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 5

ER -